To examine the potential clinical relevance of CD47 upregulation in acquired resistance to BRAF inhibitors in vivo, we took advantage of primary melanoma cell cultures of paired BRAFV600E melanoma biopsy samples from five patients pre- and post-treatment with vemurafenib [25]. The gene discussed is CD47; the disease is melanoma.